Drug Trial Radar · NCT07601646
A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Ryan Flannigan, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04 in adult males with a clinical diagnosis of Erectile Dysfunction (ED). This study aims to determine if ST-04, with or without sildenafil, will improve erectile function (EF) compared to baseline. Participants in this study will receive ST-04, a new formulation containing the vasodilator, alprostadil which is known to be an effective drug in treating erectile dysfunction. ST-04 will be dispersed along the urethra, forming a hydrogel which adheres to the lining of the urethra with the goal of penile tumescence and erection. Participants may receive up to 3 dose level escalations of ST-04 over a 12-week period, for a total of up to 11 administrations of ST-04. Dose escalation may also be done with and without sildenafil.
Conditions
- Erectile Dysfunction (ED)
- Erectile Dysfunctions
- Erectile Function
Interventions
ST-04Drug
ST-04 consists of an alprostadil polymer suspension designed for intraurethral application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Erectile Function Domain of the IIEF QuestionnaireTime frame: From baseline to 1 month after start of the last dose level (Week 4, 8, 12 respectively)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vancouver Prostate Centre
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.